The risk of thrombosis after the second dose of AstraZeneca coronavirus vaccine does not increase, according to a new study from the pharmaceutical company.
The study, published in the journal Lancet, reports that for every one million people who received the first dose of the vaccine, there were 8,1 reports of low platelet thrombosis, known as Thrombocytopenia Syndrome.
The study looked at 49,23 million vaccinations in the EU and the UK by the end of April.
For every million of the 5,62 million second-dose cases that were also studied, there were 2,3 cases of thrombosis.
AstraZeneca executive vice president Mene Pangalos said that "unless Thrombocytopenia Syndrome has been identified after the first dose, these results support the administration of the second dose as appropriate."
The company also said that there are no specific risk factors or specific cause for the thrombosis associated with the drug and that studies are ongoing.